Cyclopamine / mtDam Cancer Research Results

Cyc, Cyclopamine: Click to Expand ⟱
Features:
Cyclopamine is a natural steroidal alkaloid derived from the corn lily, Veratrum californicum, which specifically disrupts the Hh signaling pathway.

Cyclopamine — Cyclopamine is a natural steroidal alkaloid Hedgehog pathway antagonist derived from the corn lily Veratrum californicum. It is formally a small-molecule phytochemical / steroidal alkaloid and experimental Smoothened inhibitor. Cyclopamine is best treated as a preclinical tool compound and pharmacologic scaffold rather than a clinically deployed anticancer drug, because systemic translation is constrained by poor solubility, acid instability, limited pharmacokinetics, and developmental toxicity risk.

Primary mechanisms (ranked):

  1. Direct Smoothened inhibition with downstream suppression of canonical Hedgehog signaling and GLI transcriptional output.
  2. Suppression of Hedgehog-dependent cancer cell proliferation, survival, tumor growth, invasion, and metastatic behavior in susceptible models.
  3. Inhibition or reversal of epithelial-mesenchymal transition programs, including reduced GLI1, Snail, Twist, and N-cadherin with increased E-cadherin in context-dependent models.
  4. Reduction of cancer stem-like or tumor-initiating phenotypes where Hedgehog signaling maintains stemness or stromal tumor support.
  5. Secondary noncanonical effects, including Wnt beta-catenin pathway suppression and mitochondrial respiration impairment in some models.

Bioavailability / PK relevance: Cyclopamine has poor aqueous solubility, acid-sensitive conversion to less active products under gastric-like conditions, and suboptimal systemic pharmacokinetics. These constraints explain why clinically used Hedgehog inhibitors are synthetic SMO inhibitors or derivatives rather than cyclopamine itself.

In-vitro vs systemic exposure relevance: Many in-vitro studies use micromolar cyclopamine concentrations, often exceeding what is realistically attractive for systemic exposure with the parent compound. Interpretation should therefore distinguish pathway-probe activity from clinically achievable drug exposure. The compound is concentration-driven, not field-based or device-based.

Clinical evidence status: Preclinical tool compound. Cyclopamine has strong mechanistic and animal-model evidence for Hedgehog pathway inhibition, but it is not an approved anticancer drug and has not become a standard clinical intervention. Clinical translation of this mechanism is represented by approved SMO inhibitors such as vismodegib, sonidegib, and glasdegib, not by cyclopamine itself.

Cyclopamine cancer mechanism table

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 SMO Hedgehog GLI axis SMO signaling ↓; GLI1 ↓; PTCH1 output ↓ Developmental and progenitor Hedgehog signaling ↓ R/G Core pathway blockade Most central and most reproducible mechanism. Relevant mainly in tumors with ligand-dependent Hedgehog activity, PTCH loss, SMO activation, or Hedgehog-dependent stromal support.
2 Proliferation and cell cycle control Proliferation ↓; G1 arrest ↑; tumor growth ↓ Normal proliferating progenitor activity may ↓ G Growth suppression Observed across multiple preclinical cancer models, but magnitude depends on Hedgehog dependency and concentration.
3 EMT invasion and metastasis EMT ↓; invasion ↓; migration ↓; metastasis ↓ Context-dependent effects on wound repair and developmental motility programs G Anti-invasive shift Mechanistically linked to GLI1 and EMT transcription factors. Direction aligns with E-cadherin ↑ and N-cadherin, Snail, or Twist ↓ in selected models.
4 Cancer stem-like signaling Self-renewal and tumor-initiating phenotype ↓ Normal stem or progenitor Hedgehog support may ↓ G Stemness suppression Important in tumors where Hedgehog signaling maintains cancer stem-like compartments or therapy-resistant subpopulations.
5 Stromal tumor support Paracrine tumor support ↓ in some models Stromal repair and tissue homeostasis may be altered G Microenvironment modulation Therapeutic leverage is context-dependent. In pancreatic cancer, later clinical experience with Hedgehog inhibition showed that stromal effects can be complex and not uniformly beneficial.
6 Wnt beta-catenin crosstalk Beta-catenin TCF transcription ↓; E-cadherin ↑ Context-dependent epithelial homeostasis effects G Secondary pathway suppression Reported in colorectal cancer models. Best interpreted as downstream or pathway-crosstalk biology rather than the primary drug target.
7 Mitochondrial respiration Aerobic respiration ↓; mitochondrial function ↓ Potential mitochondrial stress in normal cells R/G Secondary bioenergetic stress Reported especially with cyclopamine tartrate. This may contribute to cytotoxicity but is not the canonical defining mechanism.
8 Chemosensitization and radiosensitization Therapy resistance programs ↓ in Hedgehog-dependent contexts Normal-tissue effects uncertain G Adjunctive sensitization potential Preclinical rationale exists through Hedgehog and GLI suppression, but parent cyclopamine is not clinically established as an adjunct.
9 Clinical Translation Constraint In-vitro potency does not reliably translate to systemic therapy Teratogenic and developmental pathway risk is high G Translation limitation Poor solubility, acid instability, PK limitations, and developmental toxicity make cyclopamine mainly a research compound and scaffold for better SMO inhibitors.

P: 0–30 min

R: 30 min–3 hr

G: >3 hr
mtDam, mitochondrial damage: Click to Expand ⟱
Source:
Type:
Mitochondrial damage can lead to a shift from oxidative phosphorylation to glycolysis, a process known as the Warburg effect. This shift can provide cancer cells with a selective advantage, allowing them to grow and proliferate more rapidly.
Mitochondrial Damage can also lead to cell death of cancer cells.
Scientific Papers found: Click to Expand⟱
6249- Cyc,    Cyclopamine tartrate, an inhibitor of Hedgehog signaling, strongly interferes with mitochondrial function and suppresses aerobic respiration in lung cancer cells
- in-vitro, NSCLC, A549 - in-vitro, NSCLC, H1299
HH↓, OCR↓, TumCP↓, Apoptosis↑, ROS↑, MMP↑, mtDam↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↑, 1,   mtDam↑, 1,   OCR↓, 1,  

Cell Death ⓘ

Apoptosis↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

HH↓, 1,  

Migration ⓘ

TumCP↓, 1,  
Total Targets: 7

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: mtDam, mitochondrial damage
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:66  Target#:614  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page